Moxifloxacin Krka (Moxifloxacin)

• Moxifloxacin is a broad‑spectrum fluoroquinolone indicated for several serious bacterial infections.
• Community‑acquired bacterial pneumonia: effective in eradicating the causative pathogens and improving clinical outcomes.
• Acute bacterial sinusitis: reduces bacterial load and alleviates sinus inflammation.
• Skin and soft tissue infections: provides rapid bacterial clearance and promotes healing.
• Complicated intra‑abdominal infections: targets mixed aerobic and anaerobic organisms to resolve infection.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By stabilizing the enzyme‑DNA complex, it prevents the resealing of DNA strands, leading to bacterial cell death and a bactericidal effect against susceptible organisms.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, occasionally watery.
• Headache: transient cranial discomfort.
• Rash: mild skin erythema or pruritus.
• Elevated liver enzymes: transient increase in hepatic transaminases.
• Transient dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects

• Tendon rupture: sudden tendon pain or rupture, especially in the Achilles.
• QT interval prolongation: risk of cardiac arrhythmias.
• Clostridioides difficile infection: severe colitis following disruption of gut flora.
• Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Hepatic failure: rare but potentially life‑threatening liver injury.
• Peripheral neuropathy: persistent numbness or tingling in extremities.

• When prescribing Moxifloxacin, clinicians should consider several safety measures.
• Renal impairment: monitor renal function and adjust therapy as needed.
• QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances.
• Concomitant corticosteroids: increased risk of tendon rupture; use with caution.
• Pregnancy and lactation: prescribe only if benefits outweigh potential risks.
• Tendon disorders: discontinue immediately if tendon pain, swelling, or rupture occurs.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce moxifloxacin absorption.
• Corticosteroids: increase risk of tendon rupture.
• Warfarin: enhanced anticoagulant effect, may raise INR.
• Strong CYP1A2 inhibitors (e.g., fluconazole): increase plasma concentrations.
• QT‑prolonging agents (e.g., macrolides): additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• NSAIDs: potential for central nervous system stimulation.
• Theophylline: may raise serum theophylline levels.
• Diabetes medications (e.g., insulin): possible alteration of glucose control.
• Proton pump inhibitors: may modestly affect absorption.
• Statins: increased risk of myopathy when combined.